US rare diseases specialist Soligenix closed 19% lower after Tuesday’s trading following news of a setback with its lead drug candidate. 15 February 2023
Positive Phase III data for Bristol Myers-Squibb’s Abecma (idecabtagene vicleucel) underscore the potential of the firm’s CAR-T cell therapy in multiple myeloma 13 February 2023
Boston-based Garuda Therapeutics, a company creating off-the-shelf, durable blood stem cell-based cellular therapies, is $62 million richer. 7 February 2023
French drugmaker Sanofi looked set to close Friday’s trading 2% down after presenting its latest financial results and outlook for 2023. 3 February 2023
Positive results from the Phase III CARTITUDE-4 study show the novel BCMA-directed T-cell therapy Carvykti (ciltacabtagene autoleucel) performed well in the tre 30 January 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.